132 related articles for article (PubMed ID: 1352908)
1. Gastroprotective and antisecretory effects of ebrotidine.
Konturek SJ; Maczka J; Kaminski K; Sito E; Torres J; Oleksy J
Scand J Gastroenterol; 1992 Jun; 27(6):438-42. PubMed ID: 1352908
[TBL] [Abstract][Full Text] [Related]
2. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[TBL] [Abstract][Full Text] [Related]
3. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T; Majka J; Konturek SJ
Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
[TBL] [Abstract][Full Text] [Related]
4. Ebrotidine.
Patel SS; Wilde MI
Drugs; 1996 Jun; 51(6):974-80; discussion 981. PubMed ID: 8736619
[TBL] [Abstract][Full Text] [Related]
5. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
6. Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine.
Arroyo MT; Lanas A; Sáinz R
Eur J Gastroenterol Hepatol; 2000 Mar; 12(3):313-8. PubMed ID: 10750652
[TBL] [Abstract][Full Text] [Related]
7. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
Gabryelewicz A; Czajkowski A; Skrodzka D; Marlicz K; Luca de Tena F; Aldeguer M; Chantar C; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
[TBL] [Abstract][Full Text] [Related]
9. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
10. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
11. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
12. Effects of ebrotidine on aspirin-induced gastric mucosal damage and blood flow in humans.
Konturek SJ; Kwiecien N; Sito E; Obtulowicz W; Kaminski K; Oleksy J
Scand J Gastroenterol; 1993 Dec; 28(12):1047-50. PubMed ID: 7905660
[TBL] [Abstract][Full Text] [Related]
13. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
Slomiany BL; Piotrowski J; Murty VL; Slomiany A
Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
Puscas I; Puscas C; Coltau M; Pasca R; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
[TBL] [Abstract][Full Text] [Related]
16. Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.
Slomiany BL; Piotrowski J; Majka J; Czajkowski A; Slomiany A; Gabryelewicz A
Gen Pharmacol; 1995 Sep; 26(5):1039-44. PubMed ID: 7557247
[TBL] [Abstract][Full Text] [Related]
17. Ebrotidine--a nostrum for ulcer.
Grover JK; Rathi SS; Vats V
Trop Gastroenterol; 1997; 18(3):111-3. PubMed ID: 9385853
[No Abstract] [Full Text] [Related]
18. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
Muñoz-Navas M; Honorato J; Reina-Ariño M; Márquez M; Herrero E; Villamayor F; Torres J; Roset PN; Fíllat O; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
[TBL] [Abstract][Full Text] [Related]
19. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
Palop D; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
[TBL] [Abstract][Full Text] [Related]
20. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]